CTXR Stock Summary and Trading Ideas (Citius Pharmaceuticals | NASDAQ:CTXR)

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Citius Pharmaceuticals trades on the NASDAQ stock market under the symbol CTXR.

As of April 23, 2026, CTXR stock price climbed to $0.93 with 3,147,969 million shares trading.

CTXR has a beta of 2.81, meaning it tends to be more sensitive to market movements. CTXR has a correlation of 0.12 to the broad based SPY ETF.

CTXR has a market cap of $20.88 million. This is considered a Sub-Micro Cap stock.

Last quarter Citius Pharmaceuticals reported $4 million in Revenue and -$.38 earnings per share. This beat revenue expectation by $489,000 and missed earnings estimates by -$.08.

In the last 3 years, CTXR traded as high as $40.47 and as low as $.63.

The top ETF exchange traded funds that CTXR belongs to (by Net Assets): VXF.

CTXR has underperformed the market in the last year with a return of +13.8%, while SPY returned +35.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CTXR shares. However, CTXR has outperformed the market in the last 3 month and 2 week periods, returning +9.8% and +12.4%, while SPY returned +3.1% and +4.8%, respectively. This indicates CTXR has been having a stronger performance recently.

CTXR support price is $.81 and resistance is $.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTXR shares will trade within this expected range on the day.